Practice

Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical

Read Article
US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL
Dr. John Cush @RheumNow( View Tweet )
A provacative OPINION piece in The Hill asks, is "China is quietly taking control of US medicine..." Should the US & FDA facilitating, ignorning or opposing Chinas influence? Issues of transparency, manufacturing, global supply chain, outsourcing early phase RCTs, etc. https://t.co/4vveTR8UK8
Dr. John Cush @RheumNow( View Tweet )
LLMs in SLE: From Patient Education to Clinical Decision Support The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical https://t.co/0rhada36Ji
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
pill pillbox adherence

Lessons on Non-adherence

Sheila Reyes, MD

Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences

Read Article
EULAR.Docs.APP

Day 4 EULAR Report

Jack Cush, MD

The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and

Read Article
Steroid use remain common in rheumatology, despite risks even low-dose, especially for older adults. "Steroids and Me" (Sam) provides online patient education ~5 minutes. @RheumNow #EULAR2026 POS1388

Jiha Lee @JihaRheum( View Tweet )

Patient-initiated telemedicine follow-up cut rheumatology visits by 25% in stable #SpA, but not equally for everyone. Reductions were greatest in men, axSpA, bDMARD users, and the oldest patients (64+, 34% fewer visits). Patient-centered care delivery @RheumNow #EULAR2026 POS1345

Jiha Lee @JihaRheum( View Tweet )

ILD.colors

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest

Jiha Lee, MD

At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool

Read Article
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Dr. John Cush @RheumNow( View Tweet )
#EULAR2026 Signing off from the conference 🚆. A lot of learning points and things to consider for tomorrow’s practice, caught up with colleagues and formed new collaborations. Thank you @eular_org. Hope you enjoyed our @RheumNow coverage. See you in Berlin 🇩🇪 #EULAR2027 https://t.co/nyaBnHLrxr

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis. @ElenaNikiUK @RheumNow #EULAR2026 https://t.co/UmB63QBl7N

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
How many ‘cars’ are there? crowded #CAR-T ‘driving’ innovation at #EULAR2026 >90 abstracts w CAR-T in title Lessons learned Maybe #immune #reset is not always the goal ➡️vs ’#immune #dimming How long are effects? safety looks good PT selection is key Early, no damage @RheumNow https://t.co/6jii5MBJcJ

Links:

Janet Pope @Janetbirdope( View Tweet )
RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush @RheumNow( View Tweet )

Digitalization in rheumatology. How can it help? Potential opportunities @RheumNow #EULAR2026 https://t.co/KKImSNLgbq

Links:

Bella Mehta @bella_mehta( View Tweet )
🩺🌳When good clinical practice meets reducing environmental burden of healthcare: Rheumatologists can do a lot! Less is more ⬇️ Thank you @eular_org for planning environmental awareness sessions Looking forward to #greener congresses #EULAR2026 @RheumNow https://t.co/5FwARRi92m

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated: High carbon footprint! #EULAR2026 @rheumnow https://t.co/BAuzQuZ0Iv

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Have you ever thought of diclofenac as an environmental pollutant? Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026 @rheumnow https://t.co/RJWB6DmiZh

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
EULAR.Docs.APP

Day 2 Report from EULAR 2026

Jack Cush, MD

Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease.  Here are a few of my favorites from Day 2. 

Read Article
Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM

Links:

Jiha Lee @JihaRheum( View Tweet )
Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
elderly hands

A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

Jiha Lee, MD

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology

Read Article

Therapeutic Updates

Lupus Nephritis

Sponsored by RheumNow
Management of CKD in Lupus Nephritis Patients
View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.
Read Post

Recent Blogs

Autoantibodies Anonymous

Artie Kavanaugh, MD
AutoAb.Token
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Advanced Practice Rheum

Difficult to Treat Rheumatoid Arthritis

Jack Cush, MD
D2T RA Cover
Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×